Richard Yeh

Richard Yeh is currently Independent Non-Executive Director at Immvira Bioscience, Inc. since 2025, Lead Independent Non-Executive Director at ADICON Holdings Ltd. since 2026, Independent Non-Executive Director at Medlive Technology Co., Ltd. since 2021, and Director at Tasly Pharmaceutical Group Co., Ltd. since 2024.
Former positions include CFO, Director & Head-Strategic Operations at Abbisko Therapeutics Co., Ltd. from 2021 to 2022; Director, Chief Operating & Financial Officer at NovaBridge Biosciences from 2022 to 2024; CFO, Executive Director & Head-Operations at Abbisko Cayman Ltd. from 2020 to 2022; Director at I-MAB Biopharma Co., Ltd.; Research Associate at Amgen, Inc.; Research Analyst at Citigroup Global Markets, Inc. (Broker); Research Associate at Canaccord Adams, Inc. from 2003 to 2004; Corporate Development Manager at GenoSpectra, Inc.; Analyst at Wyeth Pharmaceuticals LLC; Research Analyst at Needham & Co. LLC from 2005 to 2007; Head of China Healthcare Research at Citigroup Global Markets Asia Ltd.; Analyst at Goldman Sachs (Asia) LLC; and Chief Financial Officer at CStone Pharmaceuticals Co. Ltd. from 2018 to 2020.
Education includes an MBA from Cornell University conferred in 2002, graduate degree from the University of Toronto in 1995, and undergraduate degree from the University of Manitoba in 1993.